CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Lanabecestatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02663128
NCT02663128Phase 1Completed
CompareCT.gov

A Bioequivalence and Food Effect Study in Healthy Subjects Administered 2 Different Tablet Formulations of LY3314814

AstraZeneca·interventional·Posted Jan 26, 2016·Updated Nov 1, 2019

In Brief

A Phase 1 clinical trial evaluating Lanabecestat for Healthy. Completed, enrolled 18 participants.

Detailed Summary

The purpose of this study is to measure how much of a new tablet formulation of lanabecestat gets into the blood stream and how long it takes the body to get rid of it, compared to the current tablet formulation of lanabecestat. The effect of a high fat meal on how quickly the body absorbs the new tablet formulation will also be evaluated. In addition any side effects of the study drug using both the new and current tablet formulations will be evaluated. The study will last about 22 days, with screening required within 30 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
CollaboratorsEli Lilly and Company

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 26, 2016
Enrollment StartJan 31, 2016
Primary CompletionMar 31, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.4 years ago

Interventions

Lanabecestatdrug

Administered orally